Exelixis is trading 5.8% down now at $53.41 after management lowered full-year 2026 total-revenue guidance.
- August 5 earnings showed second-quarter revenue of $628.7 million, below the $636.4 million consensus estimate, despite adjusted EPS beating expectations.
- Guidance fell to $2.50-$2.55 billion from $2.525-$2.625 billion, cutting the midpoint by $50 million.
- Management cited a slower-than-expected NET indication patient ramp, intensifying concerns about near-term growth.